Perspective Therapeutics’ (CATX) Outperform Rating Reiterated at Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a report released on Monday,RTT News reports. They currently have a $11.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 323.08% from the company’s previous close.

Several other brokerages have also weighed in on CATX. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Scotiabank began coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price on the stock. Finally, Oppenheimer decreased their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $14.56.

Perspective Therapeutics Trading Up 0.4 %

CATX traded up $0.01 during midday trading on Monday, hitting $2.60. The company had a trading volume of 412,031 shares, compared to its average volume of 985,297. Perspective Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.05. The firm’s 50-day simple moving average is $3.14 and its 200-day simple moving average is $7.20.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CATX. Charles Schwab Investment Management Inc. lifted its holdings in Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after purchasing an additional 298,778 shares during the last quarter. State Street Corp lifted its holdings in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after buying an additional 1,192,812 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after buying an additional 355,685 shares in the last quarter. FMR LLC boosted its position in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after acquiring an additional 44,174 shares in the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.